We are live on ! Find out more
LABT

Lakewood-Amedex Biotherapeutics
LABT

6 hedge funds and large institutions have $307K invested in Lakewood-Amedex Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5.59% more ownership

Funds ownership: 0% → 5.59% (+5.6%)

Holders
6
Holders Change
+6
Holders Change %
–
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MG
Marex Group
+$826K
2
HF
HRT Financial
New York
+$768K
3
UBS Group
UBS Group
Switzerland
+$70.3K
4
TRCT
Tower Research Capital (TRC)
New York
+$10.7K
5
Osaic Holdings
Osaic Holdings
Arizona
+$2.37K

Top Sellers

No sellers this quarter

LABT Hedge Fund Activity: Q2 2026 in Review

6 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Lakewood-Amedex Biotherapeutics (LABT) for Q2 2026, worth a combined $307K.

Buyers outnumbered sellers: 6 funds opened new LABT positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Marex Group, opening a new position worth an estimated $826K.

  • 6 institutional investors held Lakewood-Amedex Biotherapeutics (LABT) as of Q2 2026, up from 0 in Q1 2026.
  • Funds reported $307K of Lakewood-Amedex Biotherapeutics stock for Q2 2026.
  • 6 funds opened new Lakewood-Amedex Biotherapeutics positions in Q2 2026 and 0 closed out, a net change of +6 holders.
  • The largest Lakewood-Amedex Biotherapeutics buyer in Q2 2026 was Marex Group, an estimated $826K added.

Based on aggregated 13F filings for Q2 2026.